A
Alloy Therapeutics
AI-powered drug discovery and development platforms
About Alloy Therapeutics
Alloy Therapeutics is a biotechnology company that provides drug discovery and development platforms and services to biotech and pharmaceutical companies, academic founders and other research organizations. It works as a development partner and does not run a competing in-house drug pipeline.
Its main platform is ATX-Gx, a suite of transgenic mice for fully human antibody discovery, including hyperimmune and common light chain strains for multispecific antibodies. Alloy also runs antibody discovery and optimization services, mAbForge high-throughput antibody expression, Keyway TCR mimic discovery, antisense genetic medicines and pharmacology studies. AI and machine learning models trained on its own lab data support antibody design, clone selection and developability prediction.
The company earns revenue by licensing its platforms and running discovery and development programs for more than 200 partners. Through 82VS it co-creates new biotech companies built on its platforms, and Spannerwerks helps partners move candidates into the clinic.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Waltham, United States
- Employees
- 138
- Open positions
- 10
- Dealroom signal
- 76.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Verified Unicorns and $1B Exits, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Investment activity
- 10 companies, latest Oct 2025
- Capital deployed
- $108M
- Preferred round
- SEED
Knowledge graph
News
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Apr 2026 | $40M | $1B | Thiel Capital · JIC Venture Growth Investments · Ulysses Diversified Holdings · Founders Fund | ↗ |
| SERIES DOther financing | Oct 2022 | $42M | $375M | Founders Fund · Presight Capital · 8VC · Thiel Capital | ↗ |
Growth signals
Latest recorded traffic for Alloy Therapeutics is 13K monthly website visits, up 0% over the last three months. Alloy Therapeutics's team grew 3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
SpannerwerksSeattle, United StatesConsulting for drug and biologic development commercialization
→
Wheeler BioOklahoma City, United StatesBy bringing together biologics drug innovators, discovery CROs, and CDMOs accelerating the translation of therapeutic innovation to clinical impact
$140Mvaluation
Vernal BiosciencesColchester, United StatesManufacturer of high purity mRNA for research and clinical use
$105Mvaluation
Tegmine TherapeuticsSan Francisco, United States
→
Mytide TherapeuticsBoston, United StatesManufacturing custom peptides for researchers
$28Mvaluation
DeepCDR BiologicsBasel, SwitzerlandAccelerating antibody discovery & engineering with deep learning
$160Kvaluation
Voro Therapeuticsoperational
→
Aldebaran TherapeuticsWaltham, United StatesPrecision ocular medicines using antisense oligonucleotide technology
$3.2Mvaluation
Aakha BiologicsoperationalWe utilize multiple advanced antibody discovery platforms to enable experienced drug hunters to go efficiently from concept through the IND enabling stage
→
Broadwing BioSouth San Francisco, United StatesEnvisioning an end to blindness
→
Alloy Therapeutics in the Waltham ecosystem
The Alloy Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later12 investors entered at this stage
8VC
Alexandria Venture Investments
Gaingels- UHUlysses Diversified Holdings
Founders Fund
Peter Thiel
Presight Capital
Mubadala Capital- LBLuma Bio-IT
Thiel Capital
JIC Venture Growth Investments
Echo Capital
Other known investors1 additional known investor
ETH Zurich
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alloy Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alloy Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.